Provectus Pharma Updates Shareholders on 2009 Year-to-date Accomplishments

We believe the results show that PV-10 can be a viable treatment for metastatic melanoma, and we are focusing our efforts on completing the 80 patient study, while also making plans for our next steps in development.... (Continue reading)